Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 11 2020
18 11 2020
Historique:
received:
16
03
2020
accepted:
04
11
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
31
3
2021
Statut:
epublish
Résumé
To date, very few studies have been focused on the impact of the convergence of neuropsychiatric symptoms (NPS) and APOE ε4 on the conversion to dementia in patients with Mild Cognitive Impairment patients (MCI), and none has been based in a clinical setting. The objective of the study is to determine the predictive value of additive and multiplicative interactions of NPS and APOE ε4 status on the prediction of incident dementia among MCI patients monitored in a Memory Clinic. 1512 patients (aged 60 and older) with prevalent MCI were followed for a mean of 2 years. Neuropsychiatric symptoms were assessed at baseline using the Neuropsychiatric Inventory Questionnaire. Cox proportional hazards models were calculated. Additive interactions for depression, apathy, anxiety, agitation, appetite, or irritability and a positive ε4 carrier status were obtained, significantly increasing the hazard ratios of incident dementia (HR range 1.3-2.03). Synergistic interactions between NPS and APOE ε4 are identified among MCI patients when predicting incident dementia. The combination of the behavioral status and the genetic trait could be considered a useful strategy to identify the most vulnerable MCI patients to dementia conversion in a Memory Clinic.
Identifiants
pubmed: 33208795
doi: 10.1038/s41598-020-77023-z
pii: 10.1038/s41598-020-77023-z
pmc: PMC7674479
doi:
Substances chimiques
Apolipoprotein E4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20058Commentaires et corrections
Type : ErratumIn
Références
J Clin Exp Neuropsychol. 2012;34(2):209-19
pubmed: 22149440
Psychiatry Clin Neurosci. 2020 Dec;74(12):645-651
pubmed: 32909371
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Epidemiology. 2009 Mar;20(2):161-6
pubmed: 19034025
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Neurology. 2015 Mar 3;84(9):935-43
pubmed: 25653291
Neurosci Biobehav Rev. 2019 Jan;96:302-315
pubmed: 30513312
Am J Geriatr Psychiatry. 2005 Jul;13(7):624-7
pubmed: 16009739
Alzheimers Dement. 2013 Sep;9(5):602-8
pubmed: 23562430
Neurology. 1993 Feb;43(2):250-60
pubmed: 8094895
Dement Neuropsychol. 2008 Oct-Dec;2(4):256-260
pubmed: 29213581
Dement Geriatr Cogn Disord. 2008;25(2):115-26
pubmed: 18087152
Neurologia. 2002 Jun-Jul;17(6):317-23
pubmed: 12084358
PLoS One. 2013 Oct 16;8(10):e76436
pubmed: 24146868
Arch Gerontol Geriatr. 2016 Jul-Aug;65:231-8
pubmed: 27111252
Epidemiology. 2007 Nov;18(6):800-4
pubmed: 18049194
Neurobiol Aging. 2020 Jan;85:74-82
pubmed: 31735378
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Am J Geriatr Psychiatry. 2013 Jul;21(7):685-95
pubmed: 23567400
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
J Alzheimers Dis. 2010;19(3):761-80
pubmed: 20157235
Neurobiol Dis. 2018 Sep;117:62-71
pubmed: 29859866
Int J Geriatr Psychiatry. 2008 Feb;23(2):170-7
pubmed: 17607801
Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18
pubmed: 24632990
Alzheimers Dement. 2014 May;10(3):409-15
pubmed: 24035148
Neurology. 1998 Dec;51(6):1546-54
pubmed: 9855500
Int J Geriatr Psychiatry. 2018 Dec;33(12):1627-1634
pubmed: 30276884
Eur J Epidemiol. 2011 Jun;26(6):433-8
pubmed: 21344323
Eur J Epidemiol. 2005;20(7):575-9
pubmed: 16119429
Mol Aspects Med. 2015 Jun-Oct;43-44:25-37
pubmed: 26049034
Neuropsychology. 2007 Nov;21(6):706-12
pubmed: 17983284
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
J Alzheimers Dis. 2004 Feb;6(1):1-9
pubmed: 15004322
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9
pubmed: 11001602
Genet Anal. 1999 Feb;14(5-6):143-9
pubmed: 10084106